631 related articles for article (PubMed ID: 17005526)
1. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
2. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
3. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
4. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
5. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
Fusshoeller A; Plail M; Grabensee B; Plum J
Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
[TBL] [Abstract][Full Text] [Related]
6. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
Haag-Weber M; Krämer R; Haake R; Islam MS; Prischl F; Haug U; Nabut JL; Deppisch R;
Nephrol Dial Transplant; 2010 Jul; 25(7):2288-96. PubMed ID: 20197284
[TBL] [Abstract][Full Text] [Related]
7. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
[TBL] [Abstract][Full Text] [Related]
8. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
10. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
[TBL] [Abstract][Full Text] [Related]
11. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
[TBL] [Abstract][Full Text] [Related]
13. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study.
Cho JH; Hur IK; Kim CD; Park SH; Ryu HM; Yook JM; Choi JY; Choi HJ; Choi HJ; Park JW; Do JY; Kim YL
Nephrol Dial Transplant; 2010 Jun; 25(6):1964-73. PubMed ID: 20100731
[TBL] [Abstract][Full Text] [Related]
14. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
15. [Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].
Haag-Weber M
Wien Klin Wochenschr; 2005; 117 Suppl 6():89-97. PubMed ID: 16437339
[TBL] [Abstract][Full Text] [Related]
16. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
17. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Adv Perit Dial; 1997; 13():17-22. PubMed ID: 9360644
[TBL] [Abstract][Full Text] [Related]
18. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
19. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study.
Martikainen T; Ekstrand A; Honkanen E; Teppo AM; Grönhagen-Riska C
Scand J Urol Nephrol; 2005; 39(5):410-6. PubMed ID: 16257844
[TBL] [Abstract][Full Text] [Related]
20. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients.
Oh KH; Moon JY; Oh J; Kim SG; Hwang YH; Kim S; Lee JS; Ahn C
Nephrol Dial Transplant; 2008 Jul; 23(7):2356-64. PubMed ID: 18178604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]